TABLE 2.
Predicted steady-state mean Cmax and AUC values of adjusted regimens of ETI when coadministered with NTM treatments
| NTM treatment | ETI | ETI regimen | Cmax (mg/L) | % of value for standard-dose ETI alone | AUCa (mg · h/L) | % of value for standard-dose ETI alone |
|---|---|---|---|---|---|---|
| Rifabutin, 300 mg daily | Elexacaftor | 200 mg in a.m., 100 mg in p.m. | 8.1 | 100.0 | 161.4 | 102.2 |
| Tezacaftor | 100 mg in a.m., 50 mg in p.m. | 7.3 | 88.0 | 104.7 | 91.8 | |
| Ivacaftor | 450 mg in a.m., 375 mg in p.m. | 1.6 | 100.0 | 21.6 | 80.6 | |
| Clofazimine, 100 mg daily | Elexacaftor | 200 mg q48h | 7.5 | 92.6 | 274.8 | 87.0 |
| Tezacaftor | 100 mg q48h | 8.1 | 97.6 | 213.3 | 93.6 | |
| Ivacaftor | 150 mg daily | 2.3 | 143.8 | 74.0 | 138.1 | |
| Clarithromycin, 500 mg q12h | Elexacaftor | 200 mg q72h | 7.3 | 90.1 | 392.6 | 82.8 |
| Tezacaftor | 100 mg q72h | 9.1 | 109.6 | 348.8 | 102.0 | |
| Ivacaftor | 150 mg q72h | 3.1 | 193.8 | 147.7 | 183.7 |
a
AUC from 0 to 24 h for coadministration with rifabutin, AUC from 0 to 48 h for coadministration with clofazimine, and AUC from 0 to 72 h for coadministration with clarithromycin.